Cure My Disease

Don't miss your cure!

 Log in / Sign up

A 12-minute blood test may cut heart failure diagnosis delays

NCT ID NCT07793968

Diagnosis Sponsor: University of Stirling Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This trial tests whether a point-of-care blood test for NT-proBNP, which gives results at the bedside in about 12 minutes, can help doctors diagnose new heart failure faster in hospital patients with unexplained breathlessness. Researchers will compare time to diagnosis, time to treatment, hospital stay length, readmission, and mortality against a group of patients treated before the test was introduced. They will also ask healthcare staff about how practical and acceptable the test is in routine care. The goal is to see if faster diagnosis leads to quicker treatment and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Point-of-care NT-proBNP blood testing
What this could lead to
If it works, this could speed up heart failure diagnosis and treatment, potentially shortening hospital stays and improving patient outcomes.
What could go wrong
This is a single-site study with a retrospective comparison group, so results may not apply broadly. The test itself is safe, but faster diagnosis does not guarantee better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

252 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Presenting with new suspected heart failure * Presenting with unexplained breathlessness suggestive of heart failure * Able to provide written informed consent * Has capacity to consent to study participation Exclusion Criteria: * Previous or existing clinical diagnosis of heart failure * Aged less than 18 years * Lacks capacity to provide informed consent * Acute myocardial infarction at presentation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • University Hospital Crosshouse

    Kilmarnock, East Ayrshire, KA2 0BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.